
Dr. Benjamin H. Krasne, M.D.
Board-certified physicianBoard-certified in anesthesiology, he reads medications and metabolism with a pharmacologist's eye, which shapes how he doses weight loss and longevity care.
Weight loss
GLP-1 shots, daily pills and non-GLP-1 options, prescribed after a free visit.
Start here
Brand-name injections
Pills and other options
Tap your state
State rules change what we can offer and how fast. Pick yours.
ESA and PSD letters, semaglutide, tirzepatide and medical card pages for every state we serve.
Popular ESA cities
Mobile IV in California
Multi-cancer blood test, clinician ordered
Galleri by GRAIL is a blood test that looks for signals shared by many types of cancer. It adds to, but does not replace, the screenings you already do, and any positive result needs follow-up testing.
Free to book. You pay only if you go ahead with treatment.
A free consultation helps you decide whether a $999 test that adds to, but never replaces, routine screening makes sense for your age and risk.
A licensed U.S. clinician orders Galleri for you and sends clear instructions for arranging your blood draw.
Your clinician reviews your report with you, including what a cancer signal or a no-signal result does and does not mean.
If a cancer signal is detected, you get guidance on the follow-up imaging or other diagnostic tests needed to confirm or rule out cancer.
In a free 5–10 minute phone or video consult, you'll talk through your age, history, current screening and what the test can and can't tell you.
Galleri requires an order from a licensed clinician. If it's appropriate, yours is placed and you receive instructions for your blood draw.
The sample is collected at a draw location arranged after your order and sent to GRAIL's laboratory.
Results usually take a couple of weeks after the lab receives your sample. You'll be told either that no cancer signal was detected or that a signal was detected, with a predicted origin.
Your clinician explains the result. A detected signal needs diagnostic follow-up, typically coordinated with your primary care doctor or a specialist.
Cancer risk rises with age, and this is the group GRAIL has mainly studied and is seeking approval for.
A strong family history or other risk factors may make an additional screening layer worth discussing with a clinician.
Galleri works best as an extra step after recommended screenings, not as a shortcut around them.
If a signal is found, you'll need diagnostic tests through your own health care providers, and you should be ready for that before ordering.
Galleri isn't meant for people who are pregnant, are 21 or younger or are being treated for cancer, and it's not a way to investigate symptoms. New symptoms need an in-person evaluation.
| Feature | Galleri blood test | Standard screening tests |
|---|---|---|
| What it looks for | A signal shared by many cancer types | One cancer at a time |
| Sample | One blood draw | Imaging, scope, stool or cell sample |
| FDA status | Not FDA-approved | Established, guideline-recommended tests |
| Result | Signal or no signal; needs follow-up if positive | Depends on the test |
| Role | Adds to routine screening | Recommended by age and risk |
Most proven cancer screening tests look for one cancer at a time: a mammogram for breast cancer, a colonoscopy or stool test for colorectal cancer, a Pap or HPV test for cervical cancer, and low-dose CT for lung cancer in people at high risk. Many other cancers have no routine screening test at all.
Galleri takes a different approach. It examines fragments of DNA that cells release into the blood, looking for chemical patterns (methylation) associated with cancer. GRAIL says the test can detect a signal shared by more than 50 types of cancer, and when it finds one it predicts where in the body the signal most likely came from.
A result is not a diagnosis. A positive result means more tests, such as imaging and possibly a biopsy, are needed to find out whether cancer is present. A negative result does not rule cancer out. Galleri is not FDA-approved, and whether multi-cancer tests reduce deaths from cancer is still being studied.
No cancer signal detected: this is the most common result. It's reassuring but doesn't prove you are cancer-free, because the test can miss cancers, particularly early-stage ones. Keep up with all your recommended screenings and report new symptoms promptly.
Cancer signal detected: the report includes a predicted cancer signal origin, which helps guide where to look first. Diagnostic tests such as imaging, scopes or a biopsy are needed to confirm or rule out cancer. Some people with a detected signal turn out not to have cancer, which is called a false positive.
Multi-cancer tests are a fast-moving area. The National Cancer Institute notes that these tests have generally been better at finding advanced cancers than early ones, and that more research is needed to show whether they reduce cancer deaths. NCI has launched the Vanguard Study to learn how such tests perform in people without cancer.
GRAIL applied to the FDA for premarket approval of Galleri in January 2026, and in September 2026 an FDA advisory panel voted that its benefits outweigh its risks for adults 50 and older. The panel's vote is advice only. When this page was reviewed, the FDA had not made a decision, so Galleri remains a laboratory test that is not FDA-approved. That also means insurance rarely covers it.
Galleri is designed to sit alongside standard screening. For example, the CDC notes that the U.S. Preventive Services Task Force recommends colorectal cancer screening for adults 45 through 75. Breast, cervical and, for eligible people, lung cancer screening also remain important regardless of a Galleri result.
The blood draw is low risk. The main risks come from what a result can lead to, which is why a clinician discusses the test with you first.
Independently licensed U.S. physicians supervise every treatment we offer.

Board-certified in anesthesiology, he reads medications and metabolism with a pharmacologist's eye, which shapes how he doses weight loss and longevity care.

Trained at Columbia and Washington University, he pairs prescriptions with practical habits around food, training and sleep.

An OB-GYN for more than 40 years and a Fellow of ACOG, she leads women's health care, from perimenopause to PCOS.
Still deciding? The first consultation is free and takes about 5–10 minutes.
Book a free consultationGalleri is a multi-cancer early detection blood test made by GRAIL. It looks for DNA methylation patterns linked to cancer in fragments of DNA circulating in the blood, and predicts the likely origin if a signal is found.
The Galleri test is $999. The first consultation is free and a results review with a clinician is included. Insurance generally doesn't cover it.
No. GRAIL has applied for FDA approval, and an FDA advisory panel voted in its favor in September 2026, but the FDA had not made a decision when this page was reviewed. It is currently available as a laboratory test ordered by a licensed clinician.
No. Galleri complements standard screening and doesn't replace it. Keep up with colorectal, breast, cervical and, if eligible, lung cancer screening.
It means a cancer signal was detected, not that you definitely have cancer. Diagnostic tests such as imaging or a biopsy are needed to confirm or rule out cancer, guided by the predicted origin.
Yes. A negative result lowers the chance that one of the cancers it looks for is present, but it can miss cancers, especially at early stages. Continue routine screening and report new symptoms.
Yes. Galleri must be ordered by a licensed clinician. During your consult, the clinician decides whether the test is appropriate and places the order if so.
It has mainly been studied in adults 50 and older and in people with elevated cancer risk. It isn't intended for people who are pregnant, are 21 or younger or are in active cancer treatment.
Results usually take a couple of weeks after the lab receives your sample. Your care team will tell you when to expect them.
Your clinician explains the result and helps you arrange diagnostic follow-up, usually with your primary care doctor or a specialist. Those tests aren't included in the $999 price.
Some people repeat it once a year, but the best interval for multi-cancer testing has not been established. Your clinician can talk through whether repeating it makes sense for you.
It's an ordinary blood draw, so you may have brief discomfort or a small bruise. The larger consideration is the follow-up testing a result can lead to.
Galleri isn't designed to investigate symptoms. If you have unexplained weight loss, bleeding, a lump or other new symptoms, see a clinician in person for a diagnostic workup.
Talk with a licensed clinician for 5–10 minutes by phone or video. If Galleri suits you, they order the $999 test and review your results with you.
Medically reviewed October 2026. This page is general information and not a substitute for advice from your own clinician. Read our editorial policy.